These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18328150)

  • 1. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis.
    Kageyama Y; Takahashi M; Ichikawa T; Torikai E; Nagano A
    Clin Exp Rheumatol; 2008; 26(1):73-80. PubMed ID: 18328150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis.
    Kageyama Y; Takahashi M; Nagafusa T; Torikai E; Nagano A
    Rheumatol Int; 2008 Jan; 28(3):245-51. PubMed ID: 17661050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine in patients with rheumatoid arthritis.
    Kageyama Y; Takahashi M; Nagafusa T; Torikai E; Nagano A
    Mod Rheumatol; 2007; 17(5):398-402. PubMed ID: 17929132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship of oxidative DNA damage marker 8-hydroxydeoxyguanosine and glycoxidative damage marker pentosidine.
    Kouda K; Nakamura H; Fan W; Horiuchi K; Takeuchi H
    Clin Biochem; 2001 May; 34(3):247-50. PubMed ID: 11408024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes.
    Tsukahara H; Sekine K; Uchiyama M; Kawakami H; Hata I; Todoroki Y; Hiraoka M; Kaji M; Yorifuji T; Momoi T; Yoshihara K; Beppu M; Mayumi M
    Pediatr Res; 2003 Sep; 54(3):419-24. PubMed ID: 12761359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.
    Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K
    Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of urinary pentosidine, an advanced glycation end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress.
    Tsukahara H; Shibata R; Ohta N; Sato S; Hiraoka M; Ito S; Noiri E; Mayumi M
    Metabolism; 2003 Dec; 52(12):1601-5. PubMed ID: 14669163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    Clin Exp Rheumatol; 2006; 24(5):529-33. PubMed ID: 17181921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis.
    Takahashi M; Suzuki M; Kushida K; Miyamoto S; Inoue T
    Br J Rheumatol; 1997 Jun; 36(6):637-42. PubMed ID: 9236672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis.
    Kageyama Y; Takahashi M; Torikai E; Suzuki M; Ichikawa T; Nagafusa T; Koide Y; Nagano A
    Clin Rheumatol; 2007 Apr; 26(4):505-9. PubMed ID: 16680388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E; Kageyama Y; Takahashi M; Suzuki M; Ichikawa T; Nagafusa T; Nagano A
    Rheumatology (Oxford); 2006 Jun; 45(6):761-4. PubMed ID: 16436492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis.
    Hein GE; Köhler M; Oelzner P; Stein G; Franke S
    Rheumatol Int; 2005 Dec; 26(2):137-41. PubMed ID: 15580352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased pentosidine, an advanced glycation end-product, in urine and tissue reflects disease activity in inflammatory bowel diseases.
    Kato S; Itoh K; Ochiai M; Iwai A; Park Y; Hata S; Takeuchi K; Ito M; Imaki J; Miura S; Yakabi K; Kobayashi M
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S140-5. PubMed ID: 19120887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab.
    Gonzalez-Juanatey C; Llorca J; Sanchez-Andrade A; Garcia-Porrua C; Martin J; Gonzalez-Gay MA
    Clin Exp Rheumatol; 2006; 24(3):309-12. PubMed ID: 16870100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a urinary multi-parameter biomarker set for oxidative stress in children, adolescents and young adults.
    Tamura S; Tsukahara H; Ueno M; Maeda M; Kawakami H; Sekine K; Mayumi M
    Free Radic Res; 2006 Nov; 40(11):1198-205. PubMed ID: 17050173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis.
    Oguz FM; Oguz A; Uzunlulu M
    Acta Clin Belg; 2007; 62(4):218-22. PubMed ID: 17849692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
    Familian A; Voskuyl AE; van Mierlo GJ; Heijst HA; Twisk JW; Dijkmans BA; Hack CE
    Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
    Clin Exp Rheumatol; 2006; 24(4):373-9. PubMed ID: 16956426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
    Vis M; Nurmohamed MT; Wolbink G; Voskuyl AE; de Koning M; van de Stadt R; Twisk JW; Dijkmans BA; Lems WF
    J Rheumatol; 2005 Feb; 32(2):252-5. PubMed ID: 15693084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.